Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer drops Neurocrine deal

July 3, 2006 | A version of this story appeared in Volume 84, Issue 27

Neurocrine and Pfizer have ended a four-year-old partnership to develop Neurocrine's sleep-enhancement drug indiplon. Neurocrine will reacquire worldwide rights to the drug. The split follows notification from FDA in May that 5- and 10-mg indiplon capsules are approvable, but only with data reanalysis and possible additional studies. The 15-mg extended-release tablets were deemed not approvable. Neurocrine's stock dove 60% after that announcement and dropped another 27% on June 23 on news of the split with Pfizer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.